Overview

As the fields of genetics, medicine and therapeutics continue to converge, the management of illness at its genetic source by silencing genes via RNA interference (RNAi) holds the very real potential to revolutionize treatment on a scale not seen in decades. Tekmira is one of a handful of biotech companies around the world working to exploit the potential of RNAi to treat disease. And it is from among these unique companies that the next wave of therapeutic breakthroughs will emerge.

Tekmira is uniquely equipped to become a force in this field. Guided by a cohesive vision, the Company possesses leading technology capabilities and a solid intellectual property portfolio in the area of using lipid nanoparticle (LNP) technology to deliver siRNA (small interfering RNA) as well as other nucleic acids in the treatment of disease.

With two RNAi drug candidates in clinical development and another in preclinical development,  Tekmira is well positioned to aggressively advance its product strategy. In addition, Tekmira has collaborative or partnership agreements with leading companies in the RNAi field, including Alnylam, Roche, Pfizer, Takeda, Bristol-Myers Squibb, and Merck.

Finally, broad manufacturing capabilities and a strong capital position permit the Company to move forward decisively and build a solid base for both near and longer term growth.